In brief

• From 1 January 2027, new oncology diagnostic and treatment cards will be issued exclusively electronically as eDiLO.
• The NFZ (National Health Fund) will finance diagnostics and planned treatment of malignant neoplasms only for patients with an active DiLO or eDiLO card.
• DiLO cards issued earlier will remain valid until they are closed, so patients in treatment can continue to use them.

Electronic card replaces the paper one

New oncology diagnostic and treatment cards from 1 January 2027 will be issued exclusively as eDiLO (Wchodzi eDiLO. Od 1 stycznia ważne zmiany dla pacjentów onkologicznych – zwrotnikraka.pl). The Ministry of Health reminded of this change in its communication of 27 October. Less than two months remain until the start.

Financing only with an active card

From 1 January 2027, NFZ funds for diagnostics and planned treatment of malignant neoplasms will go exclusively to people with an active DiLO or eDiLO card. Without such a document, the service will not be covered from public funds.

Previously issued cards remain valid

DiLO cards issued before 1 January 2027 will remain valid and will be handled in the existing system until they are closed. Patients undergoing tests or therapy can therefore complete the oncology pathway they started based on their previous card.